Analysts at Leerink Partnrs issued their FY2024 earnings per share estimates for shares of Atyr PHARMA in a research report issued on Tuesday, February 18th. Leerink Partnrs analyst F. Khurshid ...

Leerink initiated coverage of aTyr Pharma with an Outperform rating and $16 price target. The firm has strong confidence aTyr’s lead program efzofitimod will be successful in its ongoing Phase 3 study ...

Equities researchers at Desjardins issued their Q1 2025 earnings estimates for iA Financial in a report issued on Wednesday, February 19th. Desjardins analyst D. Young forecasts that the company will ...